Supplementary Table TS2 from Targeting Tumor Angiogenesis with the Selective VEGFR-3 Inhibitor EVT801 in Combination with Cancer Immunotherapy

Abstract

<p>Supplementary Table S2 shows EVT801 metabolite potency and selectivity profile</p>